Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will Erode $8.2 Billion in U.S. and European Sales in 2018
WALTHAM, Mass., Sept. 15 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018. Biosimilars of these three branded agents are forecasted to erode $8.2 billion in U.S. and European sales in 2018 but they are expected to capture only $4.6 billion in sales due to their lower prices.
"Biosimilars of the five brands covered in this report (Rituxan/MabThera, Erbitux, Herceptin, Amgen's Neupogen and Neulasta) will erode $34.3 billion in brand sales during our 2008-2018 forecast period across the U.S. and Europe and save health care systems $17.3 billion in the process," stated Michael Malecki, Ph.D., analyst and product manager at Decision Resources.
The new special report entitled Biosimilars: G-CSFs and Monoclonal Antibodies in Oncology also finds that oncologists are expected to demand clinical data for biosimilars demonstrating equivalence in multiple subpopulations. That is, although a biosimilar may be labeled for use in multiple subpopulations, oncologists will not feel comfortable prescribing a biosimilar without clinical validation.
Over time, oncologists are expected to become more comfortable using biosimilars in subpopulations and/or indications for which the reference product is approved but not clinically validated. In order to slow the growth of physician comfort in this regard, makers of branded biologics should emphasize the proven efficacy records of their agents and the importance of using a fully validated therapy for patients with life-threatening disease.
"Although surveyed oncologists are the most aggressive in treating cancers, they are hesitant to prescribe a biosimilar if it has not been clinically studied for the indication they are treating, even if the biosimilar is labeled for the indication in question," added Dr. Malecki.
Decision Resources expands the scope and analysis of its biosimilars product line to include oncology, immune and infectious disease and endocrinology/nephrology in three separate reports. The new report series covers 22 key biologic brands from eight biologic classes and include surveys of 456 U.S. and European physicians and 41 managed care organization pharmacy and medical directors.
Members of the media are welcome to attend our upcoming webinar entitled Biosimilars in Oncology: A Potential $25 Billion in Lost Revenue. This webinar will be held on Thursday, October 8, 2009 at 10 a.m. U.S. Eastern Time. For more information, please contact Gisselle Morales at 781-296-2691 or by email at firstname.lastname@example.org.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 email@example.com firstname.lastname@example.org
SOURCE Decision Resources
You May Also Like